Plain-English translation of NCT05814432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new approach to treating disseminated histoplasmosis, a serious fungal infection that spreads throughout the body in people with advanced HIV. Researchers want to see if a works as well as—or better than—the standard treatment of multiple smaller doses given over two weeks. All participants will receive follow-up treatment with an oral antifungal medication for one year.
Disseminated histoplasmosis is a life-threatening infection for people with advanced HIV, especially in parts of the Americas and Brazil. The standard treatment requires access to this medication over two weeks, which is difficult in many parts of the world. This trial explores whether the medication could be given more simply—in a single high dose—while still being safe and effective.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive either a single high dose or standard multiple doses of the antifungal medication, depending on which group you are randomly assigned to. After the initial two-week treatment phase, you will take an oral antifungal medication for one year. You will have regular visits and blood tests to monitor how well the treatment is working and watch for any side effects. The study team will meet regularly to review everyone's progress and ensure the trial is safe.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
Brazil